Diabetes

December 26, 2017

Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Carnosic acid, Lycopene, Ferulic acid, and Glycyrrhizic acid (CALFAG) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 26/December/2017, 11.59 pm

Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
December 24, 2017

Molecular therapy for middle aged TIIDM patients: Verapamil, an anti-hyperglycemic medication, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 25/December/2017, 1.46 am

Introduction: What they say A study from the Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD […]
December 23, 2017

Molecular therapy for TIIDM and obesity-associated metabolic deficits: A pharmaceutical mixture (PMSFN) encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 24/December/2017, 1.01 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
December 22, 2017

Natural product therapy for body weight control, energy homeostasis and TIIDM:  A therapeutic mix (PMSFN) encompassing Pyridoxamine (PM) and Sulforaphane (SFN) decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 23/December/2017, 1.51 am

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]